Cambridge Epigenetix (CEGX), a pioneer in the development and application of epigenetic technologies, today announced the appointment of leading epigenetics-based therapeutics specialist, Professor Mark Dawson to its Scientific Advisory Board (SAB).
Professor Dawson brings a wealth of experience in the translation of cancer epigenetics research to clinical practice. The appointment further strengthens CEGX’s panel of opinion leaders providing expert advice across the Company’s key focus areas of epigenetics, oncology, liquid biopsy, diagnostic and therapeutic development.
Mark Dawson, MBBS (Hons), BMedSci, FRACP, FRCPA, PhD is Professor in the Sir Peter MacCallum Department of Oncology and Centre for Cancer Research at the University of Melbourne, where he is the Program Head of the Translational Haematology Program, Group Leader of the Cancer Epigenetics Laboratory and Consultant Haematologist in the Department of Haematology. Professor Dawson’s research is focused on epigenetic regulation in normal and malignant haematopoiesis and he is a leading expert on the development of targeted epigenetics-based therapeutics. He has helped to develop BET inhibitors, a novel epigenetic cancer therapy, which has entered early-phase clinical trials for patients with haematological cancers, and has significant experience in studying the role of epigenetic proteins in the initiation and maintenance of a range of malignancies. He completed his clinical training in Melbourne, Australia and was awarded the prestigious General Sir John Monash Fellowship and Cambridge Commonwealth Trust Fellowship, which he used to complete his PhD at the University of Cambridge.
Dr Jason Mellad, CEO at CEGX commented: “Innovation and scientific rigour are at the heart of what we do at CEGX, which is why we’ve appointed a panel of advisors consisting of several high-profile individuals who have a list of notable achievements across our key areas of interest, to aid us in maintaining these core values and continuing to drive the development of epigenetics-based technologies. Professor Dawson has significant research and clinical expertise in epigenetics, therapeutics and oncology so we are delighted he has agreed to join our SAB.”
Professor Mark Dawson, SAB Member commented: “CEGX is a pioneer in the field of epigenetics and I look forward to helping the Company harness the power of epigenetics to develop the next generation of diagnostics and therapeutics.”
For further information, please visit https://www.cambridge-epigenetix.com/about-us/our-team/scientific-advisory-board